

**LISTING OF CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1-31. (Cancelled).

32. (Currently Amended): ~~The method of claim 23,~~ A method of inhibiting binding of a Dengue virus to a human cell, wherein the binding of the Dengue virus to the human cell is mediated at least in part by the binding of a Dengue virus effector molecule on the Dengue virus to one or more DC-SIGN receptor selected from DC-Specific ICAM-Grabbing Nonintegrin (DC-SIGN) and DC-Specific ICAM-Grabbing Nonintegrin Related (DC-SIGNR) expressed on the human cell, the method comprising:  
providing to the human cell a molecule that specifically binds to the DC-SIGN receptor;  
wherein the molecule that specifically binds to the DC-SIGN receptor is provided in an amount sufficient to inhibit the binding of the Dengue virus effector molecule to the DC-SIGN receptor to thereby inhibit binding of the Dengue virus to the human cell; and  
wherein the molecule that specifically binds to the DC-SIGN receptor is an antibody.

33. (Original): The method of 32, wherein the antibody is a monoclonal antibody.

34. (Previously Presented): The method of claim 33, wherein the monoclonal antibody is humanized.

35-105. (Cancelled).